|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Sun K, Zheng R, Zeng H, Zhang S,
Xia C, Yang Z, Li H, Zou X and He J: Cancer incidence and mortality
in China, 2014. Chin J Cancer Res. 30:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rong C, Meinert ÉFRC and Hess J: Estrogen
receptor signaling in radiotherapy: From molecular mechanisms to
clinical studies. Int J Mol Sci. 19:7132018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Mahmood S, Sapiezynski J, Garbuzenko OB
and Minko T: Metastatic and triple-negative breast cancer:
Challenges and treatment options. Drug Deliv Transl Res.
8:1483–1507. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jang HJ, Lee HS, Burt BM, Lee GK, Yoon KA,
Park YY, Sohn BH, Kim SB, Kim MS, Lee JM, et al: Integrated genomic
analysis of recurrence-associated small non-coding RNAs in
oesophageal cancer. Gut. 66:215–225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mavrakis KJ, Van Der Meulen J, Wolfe AL,
Liu X, Mets E, Taghon T, Khan AA, Setty M, Rondou P, Vandenberghe
P, et al: A cooperative microRNA-tumor suppressor gene network in
acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet. 43:673–678.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Guo Y, Liang X, Sun M, Wang G, De W
and Wu W: MicroRNA-223 functions as an oncogene in human gastric
cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol.
138:763–774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei Y, Yang J, Yi L, Wang Y, Dong Z, Liu
Z, Ou-Yang S, Wu H, Zhong Z, Yin Z, et al: MiR-223-3p targeting
SEPT6 promotes the biological behavior of prostate cancer. Sci Rep.
4:75462014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fazi F, Racanicchi S, Zardo G, Starnes LM,
Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco
F, et al: Epigenetic silencing of the myelopoiesis regulator
microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell. 12:457–466.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang Y, Wang Y, Chen Q, Qiu N, Zhao Y and
You X: MiR-223 inhibited cell metastasis of human cervical cancer
by modulating epithelial-mesenchymal transition. Int J Clin Exp
Pathol. 8:11224–11229. 2015.PubMed/NCBI
|
|
11
|
Zhao FY, Han J, Chen XW, Wang J, Wang XD,
Sun JG and Chen ZT: miR-223 enhances the sensitivity of non-small
cell lung cancer cells to erlotinib by targeting the insulin-like
growth factor-1 receptor. Int J Mol Med. 38:183–191. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshikawa M, Iinuma H, Umemoto Y,
Yanagisawa T, Matsumoto A and Jinno H: Exosome-encapsulated
microRNA-223-3p as a minimally invasive biomarker for the early
detection of invasive breast cancer. Oncol Lett. 15:9584–9592.
2018.PubMed/NCBI
|
|
13
|
Nieto MA, Huang RYJ, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2106. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y and Zhou BP: Epithelial-mesenchymal
transition-a hallmark of breast cancer metastasis. Cancer Hallm.
1:38–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye X, Tam WL, Shibue T, Kaygusuz Y,
Reinhardt F, Ng Eaton E and Weinberg RA: Distinct EMT programs
control normal mammary stem cells and tumour-initiating cells.
Nature. 525:256–260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krebs AM, Mitschke J, Lasierra Losada M,
Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D,
Reichardt W, Bronsert P, et al: The EMT-activator Zeb1 is a key
factor for cell plasticity and promotes metastasis in pancreatic
cancer. Nat Cell Biol. 19:518–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kar R, Jha NK, Jha SK, Sharma A, Dholpuria
S, Asthana N, Chaurasiya K, Singh VK, Burgee S and Nand P: A
‘NOTCH’ Deeper into the epithelial-to-mesenchymal transition (EMT)
program in breast cancer. Genes. 10:9612019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng Y and Pan D: The hippo signaling
pathway in development and disease. Dev Cell. 50:264–282. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao B, Lei QY and Guan KL: The Hippo-YAP
pathway: New connections between regulation of organ size and
cancer. Curr Opin Cell Biol. 20:638–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moleirinho S, Chang N, Sims AH,
Tilston-Lünel AM, Angus L, Steele A, Boswell V, Barnett SC, Ormandy
C, Faratian D, et al: KIBRA exhibits MST-independent functional
regulation of the Hippo signaling pathway in mammals. Oncogene.
32:1821–1830. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu LL, Zhao H, Ma TF, Ge F, Chen CS and
Zhang YP: Identification of valid reference genes for the
normalization of RT-qPCR expression studies in human breast cancer
cell lines treated with and without transient transfection. PLoS
One. 10:e01170582015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Azimi A, Majidinia M, Shafiei-Irannejad V,
Jahanban-Esfahlan R, Ahmadi Y, Karimian A, Mir SM, Karami H and
Yousefi B: Suppression of p53R2 gene expression with specific siRNA
sensitizes HepG2 cells to doxorubicin. Gene. 642:249–255. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang G, Liu J, Wang Q, Huang X, Yang R,
Pang Y and Yang M: MicroRNA-223-3p regulates ovarian cancer cell
proliferation and invasion by targeting SOX11 expression. Int J Mol
Sci. 18:12082017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ji Q, Xu X, Song Q, Xu Y, Tai Y, Goodman
SB, Bi W, Xu M, Jiao S, Maloney WJ and Wang Y: miR-223-3p inhibits
human osteosarcoma metastasis and progression by directly targeting
CDH6. Mol Ther. 26:1299–1312. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jabłońska-Trypuć A, Matejczyk M and
Rosochacki S: Matrix metalloproteinases (MMPs), the main
extracellular matrix (ECM) enzymes in collagen degradation, as a
target for anticancer drugs. J Enzyme Inhib Med Chem. 31:177–183.
2016. View Article : Google Scholar
|
|
30
|
Song X, Zhu M, Zhang F, Zhang F, Zhang Y,
Hu Y, Jiang L, Hao Y, Chen S, Zhu Q, et al: ZFX promotes
proliferation and metastasis of pancreatic cancer cells via the
MAPK pathway. Cell Physiol Biochem. 48:274–284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang ZC, Yi MJ, Ran N, Wang C, Fu P, Feng
XY, Xu L and Qu ZH: Transforming growth factor-β1 induces bronchial
epithelial cells to mesenchymal transition by activating the Snail
pathway and promotes airway remodeling in asthma. Mol Med Rep.
8:1663–1668. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rout-Pitt N, Farrow N, Parsons D and
Donnelley M: Epithelial mesenchymal transition (EMT): A universal
process in lung diseases with implications for cystic fibrosis
pathophysiology. Respir Res. 19:1362018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Royer C and Lu X: Epithelial cell
polarity: A major gatekeeper against cancer? Cell Death Differ.
18:1470–1477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mathias RA, Gopal SK and Simpson RJ:
Contribution of cells undergoing epithelial-mesenchymal transition
to the tumor microenvironment. J Proteomics. 78:545–557. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lv B, Yang X, Lv S, Wang L, Fan K, Shi R,
Wang F, Song H, Ma X, Tan X, et al: Retraction note to: CXCR4
signaling induced epithelial-mesenchymal transition by PI3K/AKT and
ERK pathways in glioblastoma. Mol Neurobiol. 54:2380. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Badouel C, Garg A and McNeill H: Herding
Hippos: Regulating growth in flies and man. Curr Opin Cell Biol.
21:837–843. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ehmer U and Sage J: Control of
proliferation and cancer growth by the Hippo signaling pathway. Mol
Cancer Res. 14:127–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He
J, Wang H, Xiao W, Li L, Chu Q, et al: Mutual interaction between
YAP and CREB promotes tumorigenesis in liver cancer. Hepatology.
58:1011–1020. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jiang Z, Zhou C, Cheng L, Yan B, Chen K,
Chen X, Zong L, Lei J, Duan W, Xu Q, et al: Inhibiting YAP
expression suppresses pancreatic cancer progression by disrupting
tumor-stromal interactions. J Exp Clin Cancer Res. 37:692018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu H, Du S, Lei T, Wang H, He X, Tong R
and Wang Y: Multifaceted regulation and functions of YAP/TAZ in
tumors (Review). Oncol Rep. 40:16–28. 2018.PubMed/NCBI
|
|
43
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP and TAZ: A signalling hub of the tumour microenvironment. Nat
Rev Cancer. 19:454–464. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ma Y, Yang Y, Wang F, Wei Q and Qin H:
Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int
J Cancer. 137:2275–2286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hergovich A: The roles of NDR protein
kinases in Hippo signalling. Genes. 7:212016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao B, Lei Q and Guan KL: Mst out and HCC
in. Cancer Cell. 16:363–364. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Basu-Roy U, Bayin NS, Rattanakorn K, Han
E, Placantonakis DG, Mansukhani A and Basilico C: Sox2 antagonizes
the Hippo pathway to maintain stemness in cancer cells. Nat Commun.
6:64112015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang H, Liu CY, Zha ZY, Zhao B, Yao J,
Zhao S, Xiong Y, Lei QY and Guan KL: TEAD transcription factors
mediate the function of TAZ in cell growth and
epithelial-mesenchymal transition. J Biol Chem. 284:13355–13362.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang M, Chen J, Su F, Yu B, Su F, Lin L,
Liu Y, Huang JD and Song E: Microvesicles secreted by macrophages
shuttle invasion-potentiating microRNAs into breast cancer cells.
Mol Cancer. 10:1172011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cao L, Zhang X, Cao F, Wang Y, Shen Y,
Yang C, Uzan G, Peng B and Zhang D: Inhibiting inducible miR-223
further reduces viable cells in human cancer cell lines MCF-7 and
PC3 treated by celastrol. BMC Cancer. 15:8732015. View Article : Google Scholar : PubMed/NCBI
|
